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Background: The MiStent® consists of a cobalt chromium stent with a PLGA absorbable polymer that elutes sirolimus. DESSOLVE-I is a 
prospective, single-arm, FIM trial that enrolled 30 patients with follow-up at 4, 6, or 8 months (10 patients each) and 18 months (all patients). This 
study aimed to evaluate the arterial response to MiStent in the 8-month cohort.
Methods: Serial IVUS was performed to obtain volume index (VI: volume/length) for vessel, peri-stent plaque, neointima, and lumen at baseline 
and 8 months. Neointimal obstruction (neointimal volume / stent volume, %) and cross-sectional narrowing (CSN: neointimal area / stent area, 
%) were calculated. The neointimal roughness (variability) was evaluated by standard deviation of neointimal thickness along the entire stented 
segment.
Results: At baseline, no dissection and one incomplete stent apposition (ISA) was detected. At follow-up, mild neointimal proliferation was 
observed; however, no case showed significant lumen encroachment (max CSN>50%). Neointimal roughness was 0.04±0.03 mm, indicating 
relatively even neointimal distribution along the stented segment. Despite the slight increase in vessel and peri-stent plaque, no case showed 
excessive vessel remodeling or late-acquired ISA.
Conclusion: The first-in-human IVUS results from the DESSOLVE-I 8-month cohort suggest synergy of sirolimus and absorbable polymer, balancing 
in-stent neointimal suppression with peri-stent vessel integrity. Longer follow-up is currently ongoing.
Baseline 8 months P value
Vessel VI (mm3/mm) 13.8±4.0 14.8±4.1 0.005
Peri-stent plaque VI (mm3/mm) 7.0±2.6 7.7±2.8 0.030
Lumen VI (mm3/mm) 6.7±1.8 6.1±1.5 0.006
Minimum lumen area (mm2) 5.5±1.2 4.7±1.0 0.030
Neointimal obstruction (%) NA 10.9±4.6 NA
Maximum CSN (%) NA 24.9±11.3 NA
Stents with maximum CSN>50% (%) NA 0 NA
Neointimal roughness (mm) NA 0.04±0.03 NA
